Μπανγκλαντές - Αγγλικά - DGDA (Directorate General of Drug Administration)

deeplaid pharmaco ltd. (homoeo) - abies nigra - liquid

Μπανγκλαντές - Αγγλικά - DGDA (Directorate General of Drug Administration)

new life & company (pvt) ltd. (homoeo) - abies nigra - liquid

Καναδάς - Αγγλικά - Health Canada

cutter med & biol, division of miles canada ltd. - rabies immunoglobulin (human) - liquid - 16.5% - rabies immunoglobulin (human) 16.5% - serums

Καναδάς - Αγγλικά - Health Canada

pasteur mÉrieux serums et vaccins, s.a. - rabies immunoglobulin (human) - liquid - 150unit - rabies immunoglobulin (human) 150unit - serums

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

natural health supply - rabies virus (unii: i0v66ki1ld) (rabies virus - unii:i0v66ki1ld) - rabies virus 30 [hp_c] - indications: to be used for acute, self-limiting conditions according to standard homeopathic indications.

Ηνωμένο Βασίλειο - Αγγλικά - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - rabies virus inactivated - powder and solvent for suspension for injection

Ηνωμένο Βασίλειο - Αγγλικά - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - rabies virus inactivated - powder and solvent for suspension for injection

Ηνωμένο Βασίλειο - Αγγλικά - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - rabies virus inactivated - powder and solvent for solution for injection

Ηνωμένο Βασίλειο - Αγγλικά - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - rabies virus inactivated - powder and solvent for suspension for injection

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

grifols usa, llc - human rabies virus immune globulin (unii: 95f619atq2) (human rabies virus immune globulin - unii:95f619atq2) - human rabies virus immune globulin 300 [iu] in 1 ml - hyperrab is a human rabies immune globulin indicated for postexposure prophylaxis, along with rabies vaccine, for all persons suspected of exposure to rabies. limitations of use persons who have been previously immunized with rabies vaccine and have a confirmed adequate rabies antibody titer should receive only vaccine.(1-3) for unvaccinated persons, the combination of hyperrab and vaccine is recommended for both bite and nonbite exposures regardless of the time interval between exposure and initiation of postexposure prophylaxis.(1-3) beyond 7 days (after the first vaccine dose), hyperrab is not indicated since an antibody response to vaccine is presumed to have occurred. none. risk summary there are no data with hyperrab use in pregnant women to inform a drug-associated risk.  animal reproduction studies have not been conducted with hyperrab.  it is not known whether hyperrab can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.  hyperrab should be given to a pregna